FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956131569> ?p ?o ?g. }

• W2956131569 endingPage "S226" @default.
• W2956131569 startingPage "S226" @default.
• W2956131569 abstract "To assess retrospectively the relative efficacy, safety and tolerability of brexpiprazole versus lurasidone in the acute and maintenance phases of schizophrenia. A systematic literature review identified RCTs of pharmacological treatments for adults with schizophrenia. Twelve acute studies (5 brexpiprazole, 7 lurasidone) and two maintenance studies (one brexpiprazole, one lurasidone) met pre-specified inclusion criteria. Bayesian indirect comparisons were conducted using both fixed (FE) and random-effect (RE) models. RE model comparisons showed no meaningful difference between brexpiprazole and lurasidone for change from baseline (CFB) in PANSS total score and CGI-S in the acute phase (median difference [MD] vs. lurasidone=2.58 [95% credible interval (CrI): -0.67, 5.88]; MD=0.15 [95% CrI: -0.18, 0.51]). In the maintenance phase, brexpiprazole showed lower risk of relapse versus lurasidone (hazard ratio=0.44 [95% CrI: 0.20, 0.91]). In the acute phase, brexpiprazole was associated with fewer akathisia occurrences and study withdrawals due to adverse events compared to lurasidone (odds ratio [OR] =0.21 [95% CrI: 0.06, 0.62]; OR=0.45 [95% CrI: 0.20, 0.97], respectively). In the acute phase brexpiprazole showed a higher absolute CFB in body weight compared to lurasidone (MD=0.55 kg [95% CrI: 0.13, 0.97]), while the incidence of clinically significant weight gain (≥7% CFB) was within sampling error (OR=1.92 [95% CrI: 0.88, 4.16]). No differences between treatments were observed for remaining safety and tolerability outcomes in either phase. Conclusions were robust to model choice and sensitivity analyses. These indirect analyses indicated that brexpiprazole had comparable efficacy to lurasidone in the acute phase and a lower risk of relapse during maintenance treatment. In the acute phase, brexpiprazole showed lower rates of akathisia and withdrawals due to AE but higher absolute body weight change versus lurasidone. Results suggest that clinicians may be able to tailor therapy to their patients’ needs when relevant comorbidities and risk factors for AEs are present." @default.
• W2956131569 created "2019-07-12" @default.
• W2956131569 creator A5024171925 @default.
• W2956131569 creator A5045788854 @default.
• W2956131569 creator A5056713947 @default.
• W2956131569 creator A5073088783 @default.
• W2956131569 creator A5075993444 @default.
• W2956131569 creator A5079547403 @default.
• W2956131569 creator A5090371498 @default.
• W2956131569 date "2019-05-01" @default.
• W2956131569 modified "2023-10-17" @default.
• W2956131569 title "PMH4 AN INDIRECT TREATMENT COMPARISON OF BREXPIPRAZOLE VERSUS LURASIDONE IN PATIENTS UNDERGOING ACUTE AND MAINTENANCE PHASE TREATMENT FOR SCHIZOPHRENIA" @default.
• W2956131569 doi "https://doi.org/10.1016/j.jval.2019.04.1050" @default.
• W2956131569 hasPublicationYear "2019" @default.
• W2956131569 type Work @default.
• W2956131569 sameAs 2956131569 @default.
• W2956131569 citedByCount "1" @default.
• W2956131569 countsByYear W29561315692021 @default.
• W2956131569 crossrefType "journal-article" @default.
• W2956131569 hasAuthorship W2956131569A5024171925 @default.
• W2956131569 hasAuthorship W2956131569A5045788854 @default.
• W2956131569 hasAuthorship W2956131569A5056713947 @default.
• W2956131569 hasAuthorship W2956131569A5073088783 @default.
• W2956131569 hasAuthorship W2956131569A5075993444 @default.
• W2956131569 hasAuthorship W2956131569A5079547403 @default.
• W2956131569 hasAuthorship W2956131569A5090371498 @default.
• W2956131569 hasBestOaLocation W29561315691 @default.
• W2956131569 hasConcept C118552586 @default.
• W2956131569 hasConcept C126322002 @default.
• W2956131569 hasConcept C197934379 @default.
• W2956131569 hasConcept C207103383 @default.
• W2956131569 hasConcept C2776412080 @default.
• W2956131569 hasConcept C2776701107 @default.
• W2956131569 hasConcept C2777393122 @default.
• W2956131569 hasConcept C2778375690 @default.
• W2956131569 hasConcept C2780494398 @default.
• W2956131569 hasConcept C44249647 @default.
• W2956131569 hasConcept C71924100 @default.
• W2956131569 hasConceptScore W2956131569C118552586 @default.
• W2956131569 hasConceptScore W2956131569C126322002 @default.
• W2956131569 hasConceptScore W2956131569C197934379 @default.
• W2956131569 hasConceptScore W2956131569C207103383 @default.
• W2956131569 hasConceptScore W2956131569C2776412080 @default.
• W2956131569 hasConceptScore W2956131569C2776701107 @default.
• W2956131569 hasConceptScore W2956131569C2777393122 @default.
• W2956131569 hasConceptScore W2956131569C2778375690 @default.
• W2956131569 hasConceptScore W2956131569C2780494398 @default.
• W2956131569 hasConceptScore W2956131569C44249647 @default.
• W2956131569 hasConceptScore W2956131569C71924100 @default.
• W2956131569 hasLocation W29561315691 @default.
• W2956131569 hasOpenAccess W2956131569 @default.
• W2956131569 hasPrimaryLocation W29561315691 @default.
• W2956131569 hasRelatedWork W2039404912 @default.
• W2956131569 hasRelatedWork W2049406823 @default.
• W2956131569 hasRelatedWork W2061864344 @default.
• W2956131569 hasRelatedWork W2067159511 @default.
• W2956131569 hasRelatedWork W2125301380 @default.
• W2956131569 hasRelatedWork W2589659500 @default.
• W2956131569 hasRelatedWork W2793227676 @default.
• W2956131569 hasRelatedWork W2995620309 @default.
• W2956131569 hasRelatedWork W4289443785 @default.
• W2956131569 hasRelatedWork W4365511387 @default.
• W2956131569 hasVolume "22" @default.
• W2956131569 isParatext "false" @default.
• W2956131569 isRetracted "false" @default.
• W2956131569 magId "2956131569" @default.
• W2956131569 workType "article" @default.